How I treat glioblastoma in older patients
- PMID: 26725536
- DOI: 10.1016/j.jgo.2015.12.001
How I treat glioblastoma in older patients
Abstract
Glioblastoma, a WHO grade IV astrocytoma, is the most common primary malignant brain tumor in adults. It is characterized by molecular heterogeneity and aggressive behavior. Glioblastoma is almost always incurable and most older patients survive less than 6 months. Supportive care with steroids and anti-epileptic drugs is critical to improving and maintain quality of life. Young age, good performance status and methylation of the methyl guanyl methyl transferase promoter are important positive prognostic factors. Several recent clinical trials suggest that there is a subset of the elderly with prolonged survival that is comparable to younger patients. Treatment of glioblastoma in older patients includes maximal safe resection followed by either radiation, chemotherapy or combined modality therapy. Recent advances suggest that some patients can avoid radiation entirely and be treated with chemotherapy alone. Decisions about therapy are individual and based on a patient's performance status, family support and molecular features. Future work needs to better determine the role for comprehensive geriatric assessments in this patient population to better identify patients who may most benefit from aggressive therapies.
Keywords: Cognitive dysfunction; Elderly; Glioblastoma; MGMT; Malignant gliomas; Radiotherapy; Temozolomide.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.Acta Oncol. 2017 Dec;56(12):1776-1785. doi: 10.1080/0284186X.2017.1332780. Epub 2017 Jul 4. Acta Oncol. 2017. PMID: 28675067 Clinical Trial.
-
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.Lancet Oncol. 2012 Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10. Lancet Oncol. 2012. PMID: 22578793 Clinical Trial.
-
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.Eur J Cancer. 2013 Jan;49(2):360-8. doi: 10.1016/j.ejca.2012.08.012. Epub 2012 Sep 10. Eur J Cancer. 2013. PMID: 22975219
-
Treatment of Glioblastoma.J Oncol Pract. 2017 Oct;13(10):629-638. doi: 10.1200/JOP.2017.025536. J Oncol Pract. 2017. PMID: 29020535 Review.
-
Treatment considerations for MGMT-unmethylated glioblastoma.Curr Neurol Neurosci Rep. 2015 Jan;15(1):507. doi: 10.1007/s11910-014-0507-z. Curr Neurol Neurosci Rep. 2015. PMID: 25394859 Review.
Cited by
-
Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data.Cancers (Basel). 2022 Dec 14;14(24):6180. doi: 10.3390/cancers14246180. Cancers (Basel). 2022. PMID: 36551664 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous